---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-037609"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:07:34.281387+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CalciMedica reports FY2023 net loss $34.4M; cash $11.2M; CARPO topline data Q2 2024

## Summary
- Cash, equivalents, and short-term investments $11.2M at Dec 31, 2023; pro forma after Jan 2024 private placement ~$25.5M, funding into 2H2025.
- Net loss $34.4M ($7.66 per share) for FY2023; total operating expenses $38.1M including $16.2M one-time charges from reverse merger.
- CARPO Phase 2b trial of Auxora in acute pancreatitis enrollment on track; topline data expected Q2 2024.
- KOURAGE Phase 2 trial for severe AKI with AHRF cleared by FDA; first patient enrollment Q2 2024, data expected 2025.
- CRSPA Phase 1/2 trial for asparaginase-induced pancreatic toxicity expanded to Phase 2; initial cohort data showed fewer hospital days.

## SEC filing metadata
- accession: 0000950170-24-037609
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000095017024037609/0000950170-24-037609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000095017024037609/calc-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-037609
- JSON: https://secwatch.observer/filing/0000950170-24-037609.json
- Plain text: https://secwatch.observer/filing/0000950170-24-037609.txt

## Key facts
- Earnings Releases
  CalciMedica, Inc. reported the year ended December 31, 2023 results: net income $34.4 million, or $7.66 per share (basic and diluted), EPS $7.66 per share (basic and diluted).
  - Period: the year ended December 31, 2023
  - Net income: $34.4 million, or $7.66 per share (basic and diluted)
  - EPS: $7.66 per share (basic and diluted)
  - Result: reported results
  source text: Net loss was $34.4 million, or $7.66 per share (basic and diluted) for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000095017024037609/0000950170-24-037609-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.